Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:MAbs
Auteurs principaux: Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://ncbi.nlm.nih.gov/pubmed/26466856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1106658
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires